logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Recurrent Pulmonary Embolism

    Medications for Recurrent Pulmonary Embolism

    FiltersReset Filters
    3 results

    • dabigatran

      (DABIGATRAN ETEXILATE)
      AvKARE
      Usage: Dabigatran etexilate is indicated for reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation, treating deep venous thrombosis and pulmonary embolism, preventing recurrence of these conditions, and for prophylaxis after hip replacement surgery in adult patients.

    • dabigatran etexilate

      (Dabigatran Etexilate)
      Alembic Pharmaceuticals Limited
      Usage: Dabigatran etexilate is indicated for reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation, treating deep venous thrombosis and pulmonary embolism after parenteral anticoagulant use, preventing recurrence of these conditions, and providing prophylaxis following hip replacement surgery in adults.

    • pradaxa

      (dabigatran etexilate mesylate)
      Boehringer Ingelheim Pharmaceuticals Inc.
      Usage: PRADAXA Capsules are indicated for reducing the risk of stroke and systemic embolism in adults with non-valvular atrial fibrillation, treating deep venous thrombosis and pulmonary embolism in adults, prophylaxis post-hip replacement surgery, and treating and preventing venous thromboembolic events in pediatric patients aged 8 to less than 18 years.